SEARCH

SEARCH BY CITATION

References

  • 1
    Mas-Coma S. Human fascioliasis. In: Cotruvo JA, Dufour A, Rees G, Bartram J, Carr R, Cliver DO, Craun GF, Fayer R, Gannon VPJ, eds. Waterborne zoonoses: identification, causes and control. London: IWA Publishing, 2004; 305322.
  • 2
    World Health Organization. Report of the WHO Informal Meeting on use of triclabendazole in fascioliasis control. Geneva: WHO, 2007.
  • 3
    Keiser J, Utzinger J. Food-borne trematodiases. Clin Microbiol Rev 2009; 22: 466483.
  • 4
    Graham CS, Brodie SB, Weller PF. Imported Fasciola hepatica infection in the United States and treatment with triclabendazole. Clin Infect Dis 2001; 33: 15.
  • 5
    Noyer CM, Coyle CM, Werner C, Dupouy-Camet J, Tanowitz HB, Wittner M. Hypereosinophilia and liver mass in an immigrant. Am J Trop Med Hyg 2002; 66: 774776.
  • 6
    Kang ML, Teo CH, Wansaicheong GK, Giron DM, Wilder-Smith A. Fasciola hepatica in a New Zealander traveler. J Travel Med 2008; 15: 196199.
  • 7
    Chand MA, Herman JS, Partridge DG, Hewitt K, Chiodini PL. Imported human fascioliasis, United Kingdom. Emerg Infect Dis 2009; 15: 18761877.
  • 8
    Arjona R, Riancho JA, Aguado JM, Salesa R, González-Marcías J. Fascioliasis in developed countries: a review of classic and aberrant forms of the disease. Medicine (Baltimore) 1995; 74: 1323.
  • 9
    Aksoy DY, Kerimoglu U, Oto A et al . Infection with Fasciola hepatica. Clin Microbiol Infect 2005; 11: 859861.
  • 10
    Marcos LA, Tagle M, Terashima A et al. Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis. Am J Trop Med Hyg 2008; 78: 222227.
  • 11
    MacLean JD, Cross J, Mahanty S. Liver, lung and intestinal fluke infections. In: Guerrant RL, Walker DH, Weller PF, eds. Tropical infectious diseases: principles, pathogens & practise, 2nd edn. Philadelphia, PA: Churchill Livingston Elsevier, 2005; 13491369.
  • 12
    Marcos LA, Terashima A, Gotuzzo E. Update on hepatobiliary flukes: fasciolasis, opisthorchiasis and clonorchiasis. Curr Opin Infect Dis 2008; 21: 523530.
  • 13
    Behar JM, Winston JS, Borgstein R. Hepatic fascioliasis at a London hospital—the importance of recognising typical radiological features to avoid a delay in diagnosis. Br J Radiol 2009; 82: e189e193.
  • 14
    Cerri GG, Alves VA, Magalhães A. Hepatosplenic Schistosomiasis mansoni: ultrasound manifestations. Radiology 1984; 153: 777780.
  • 15
    Agarwal N, Kumar S. Budd–Chiari syndrome owing to liver hydatid disease: case report and review of the literature. Ann Trop Paediatr 2009; 29: 301304.
  • 16
    Apt W, Aguilera X, Vega F et al. Prevalence of fascioliasis in humans, horses, pigs, and wild rabbits in 3 Chilean provinces. Bol Oficina Sanit Panam 1993; 115: 405414.
  • 17
    Cosme A, Ojeda E, Cilla G et al. Fasciolasis hepatobiliar. Estudio de una serie de 37 pacientes. Gastroenterol Hepatol 2001; 24: 375380.
  • 18
    Hassan MM, Farghaly AM, el-Gamal RL, el-Ridi AM. Cross-reactions in immunodiagnosis of patients infected with Schistosoma, Fasciola and Heterophyes using ELISA. J Egypt Soc Parasitol 1989; 19 (suppl 2): 845851.
  • 19
    Romasanta A, Romero JL, Arias M et al. Diagnosis of parasitic zoonoses by immunoenzymatic assays—analysis of cross-reactivity among the excretory/secretory antigens of Fasciola hepatica, Toxocara canis, and Ascaris suum. Immunol Invest 2003; 32: 131142.
  • 20
    Shehab AY, Basha LM, El-Morshedy HN, Abdel-Fattah M, Osman MM, Farag HF. Circulating antibodies and antigens correlate with egg counts in human fascioliasis. Trop Med Int Health 1999; 4: 691694.
  • 21
    Mailles A, Capek I, Ajana F, Schepens C, Ilef D, Vaillant V. Commercial watercress as an emerging source of fascioliasis in Northern France in 2002: results from an outbreak investigation. Epidemiol Infect 2006; 134: 942945.
  • 22
    Mas-Coma S, Valero MA, Bargues MD. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmission, epidemiology, evolutionary genetics, molecular epidemiology and control. Adv Parasitol 2009; 69: 41146.
  • 23
    Alcaíno H, Vega F, Gorman T. Epidemiología de la fasciolasis hepática en la VII Región Chile. Parasitol Día 1993; 17: 99106.
  • 24
    Apt W, Aguilera X, Vega F et al. Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am J Trop Med Hyg 1995; 52: 532535.
  • 25
    Millán JC, Mull R, Freise S, Richter J. The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am J Trop Med Hyg 2000; 63: 264269.
  • 26
    Jave JA, Alban M, Sapastegui C, Soriano S. Tratamiento de la fasciolasis hepática humana con triclabendazole. Rev Gastroenterol Perú 1999; 19: 216220.